RXRX Analyst Ratings
Recursion Pharmaceuticals, Inc. (RXRX) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $2.01B, listed on NASDAQ, employing roughly 600 people, carrying a beta of 1.03 to the broader market. Recursion Pharmaceuticals, Inc. Led by Najat Khan, public since 2021-04-16.
Analyst Ratings
In the October 2026 monthly count, 7 analysts rated RXRX: 2 Strong Buy, 1 Buy, 4 Hold, 0 Sell and 0 Strong Sell.
Twelve months earlier, in October 2025: 8 analysts, 1 Strong Buy, 1 Buy, 6 Hold, 0 Sell and 0 Strong Sell.
Price Targets
- Average Target
- $5.30
- Median Target
- $5.30
- High
- $5.30
- Low
- $5.30
- Targets Published, Last 12 Months
- 4
Recent Price Targets
The 4 most recent of 4 price targets published in the last 12 months.
| Date | Firm | Analyst | Target | Price When Posted |
|---|---|---|---|---|
| Aug 17, 2026 | Morgan Stanley | Not named | $5.30 | $3.12 |
| May 14, 2026 | Morgan Stanley | Not named | $5.50 | $3.08 |
| Dec 17, 2025 | UBS | Not named | $11.00 | $4.20 |
| Dec 17, 2025 | Morgan Stanley | Not named | $11.00 | $4.20 |
Recent Upgrades & Downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| May 14, 2026 | Morgan Stanley | maintain | Equal Weight | Equal Weight |
| May 7, 2026 | Needham | maintain | Buy | Buy |
| Apr 30, 2026 | JP Morgan | maintain | Overweight | Overweight |
| Feb 26, 2026 | B of A Securities | maintain | Neutral | Neutral |
| Feb 26, 2026 | Needham | maintain | Buy | Buy |
Quantitative Rating
RXRX carries a model grade of C (overall score 2 of 5), computed from six valuation and financial measures (discounted cash flow, return on equity, return on assets, debt to equity, price to earnings and price to book), each scored 1 to 5. It is not an analyst rating.
How to Read RXRX Analyst Coverage
Sell-side equity analysts publish three primary outputs: ratings (Strong Buy / Buy / Hold / Sell / Strong Sell, or firm-specific equivalents), price targets, and EPS / revenue estimate revisions. Rating consensus moves slowly relative to price; it reflects 12-month directional conviction rather than near-term momentum. Price targets are more responsive but typically drift behind realized price during sharp moves. The most actionable signal for options traders is a cluster of ratings actions across multiple firms within a short window, which compresses or expands implied volatility on a horizon of days to weeks and shifts the put-call skew toward the directional consensus. The recent-actions table above shows the five most recent firm-level changes; longer histories live behind aggregator sources.
For event-driven options sizing, pair the consensus rating and target distribution with the implied-volatility surface and dealer-positioning view. Aggressive target hikes from multiple firms tend to tighten put skew (downside protection becomes relatively cheaper); aggressive cuts widen put skew. The size of the IV response in the hours after a rating change is visible on the per-ticker volatility skew page and the gamma-exposure page, both of which show how dealer hedging propagates the analyst-driven flow into the listed options chain.
Learn how analyst ratings is reported and how to read the data →
Frequently asked RXRX analyst ratings questions
- What is the RXRX consensus price target?
- As of the latest aggregator update, Recursion Pharmaceuticals, Inc. (RXRX) carries a consensus 12-month price target of $5.30. Target ranges run from a low of $5.30 to a high of $5.30. The target is the average of the price targets published by sell-side equity analysts covering the name.
- What is the analyst rating consensus on RXRX?
- In the October 2026 monthly count, 7 analysts rated RXRX, and the distribution is concentrated at Hold: 2 Strong Buy, 1 Buy, 4 Hold, 0 Sell and 0 Strong Sell. Rating consensus moves slowly relative to price; it reflects sell-side conviction over a 12-month horizon rather than near-term momentum.
- What recent ratings actions has RXRX seen?
- The five most recent ratings actions on RXRX appear on the page above. Sell-side rating changes are watched for two reasons: an upgrade or downgrade with a meaningful target revision moves the consensus and can trigger short-term positioning shifts, and the firm-level rating cluster (multiple firms moving in the same direction within a short window) is a clearer signal than any single action. Options markets often price the implied-vol response within minutes of the announcement.
- How do analyst targets affect RXRX options pricing?
- Analyst target revisions tend to be priced in by the lit options market within minutes of publication, but persistent target drift over weeks does correlate with implied-volatility movement. Aggressive target hikes from multiple firms inside a single quarter tighten put skew (downside protection becomes cheaper relative to upside speculation); aggressive cuts widen put skew. The most actionable read is the implied-vol response in the hours after a target change, which is visible on the per-ticker volatility skew page.